Reuters logo
in 9 months
BRIEF-Intercept Pharmaceuticals receives positive CHMP opinion for ocaliva for treatment of primary biliary cholangitis in the EU
October 14, 2016 / 11:52 AM / in 9 months

BRIEF-Intercept Pharmaceuticals receives positive CHMP opinion for ocaliva for treatment of primary biliary cholangitis in the EU

1 Min Read

Oct 14 (Reuters) - Intercept Pharmaceuticals Inc :

* Intercept pharmaceuticals receives positive chmp opinion for ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis in the European Union Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below